Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trial

Presse Medicale

Volumn 33, Issue 7, 2004, Pages 474-478

  Svahn, Britt Marie ^a   Bjurman, B ^a   Myrback K E ^a   Aschan, J ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BLOOD COMPATIBILITY; CAREGIVER; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HOME CARE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MALE; PANCYTOPENIA; PARENTERAL NUTRITION; PATIENT CARE; RECIPIENT; SAFETY; TWINS; WARD;

EID: 1842853280     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98635-6     Document Type: Article

References (25)

1. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. Parts I and II. N Engl J Med 1975; 292: 832-43, 895-902.
2. Ringdén O. Allogeneic bone marrow transplantation for haematological malignancies - controversies and recent advances. Acta Oncol 1997; 36: 549-64.
3. Leiper AD. What is in store after stem-cell transplantation? Lancet 1999; 353: 1544-5.
4. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, eds. Clinical approach to infection in the immunocompromised host. New York: Alan R Liss Inc., 1983.
5. Paulin T, Ringdén O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317-28.
6. Sparrelid E, Hägglund H, Remberger M et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22: 795-800.
7. Buckner CD, Clift RA, Sanders JE et al. Protective environment for marrow transplant recipients. A prospective study. Ann Int Med 1978; 89: 893-901.
8. Daniels LE. Developing a home chemotherapy service. Intern J Palliative Nursing 1995; 1: 81-5.
9. Meisenberg B, Miller W, McMillan R et al. Outpatient high-dose chemotherapy with autologous stem cell rescue for hematologic and nonhematologic malignancies. J. Clin Oncol 1997; 15: 11-7.
10. Russell JA, Poon M-C, Jones AR et al. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet 1992; 339: 38-40.
11. Ringdén O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning including anti-T-cell antibodies. Transplantation 1998; 66: 620-5.
12. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-6.
13. Ringdén O, Ruutu T, Remberger M et al, for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-30.
14. Hassan M, Ljungman P, Bolme P et al. Busulphan bioavailability. Blood 1994; 84: 2144-50.
15. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-63.
16. Remberger M, Svahn B-M, Hentschke P et al. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-30.
17. Ringdén O, Lönnqvist B, Lundgren G et al. Experience with a cooperative bone marrow transplant program in Stockholm. Transplantation 1982; 33: 500-4.
18. Storb R, Deeg HJ, Farewell K et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-35.
19. Ringdén O, Remberger M, Mattsson J et al. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplantation 1998; 21: 43-9.
20. Ringdén O, Remberger M, Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 25: 993-6.
21. Tollemar J, Ringdén O, Boström L et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-41.
22. Scherertz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987; 83: 709-18.
23. Kelsey SM, Newland AC, van der Walt J, Doran H. Pulmonary aspergillosis in patients with leukaemia. J Clin Pathol 1990; 43: 783.
24. Navarí RM, Buckner CD, Clift RA et al. Prophylaxis of infections in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 1984; 76: 564-72.
25. Passweg JR, Rowlings PA, Atkinson KA et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998; 21: 1231-8.